2026 Grant Type 1
Here you will find a general overview of Grant Type 1 in ODIN. For full details on eligibility and expectations, consult the official ODIN Guidelines. The 2026 call guidelines for Grant Type 1 will be released by 1 March, 2026.
Large Grant for new projects:
› PARTICIPANTS: At least one academic applicant and one industry partner
› LENGTH: Up to 3 years
› BUDGET FOR EACH PROJECT: Up to DKK 6,5 Million
› TOTAL FUNDING AVAILABLE: Up to DKK 52 Million
› PURPOSE: To address complex research problems inspired by unmet clinical needs
3-Step Process and Deadlines:
STEP1. IDEAS, CHALLENGES, and/or RESOURCES are openly shared on the WorldLabs collaboration platform, and teams/projects are formed. 29 April
STEP2. ABSTRACTS are submitted for review. 16 June
STEP3. INVITED FULL-LENGTH APPLICATIONS are submitted 24 September
Anyone can post an idea, challenge or resource. All ideas and applications are posted through WorldLabs. All templates can be found in WorldLabs under the call for which you are applying.
SCIENTIFIC SCOPE
ODIN focuses on research within some of the most pressing global health challenges, where outcomes hold strong innovation potential. ODIN and its funded projects are supported financially by both the Novo Nordisk Foundation (NNF) and the Lundbeck Foundation (LF).
LF-funded Scope – up to DKK 14 million
› Diseases of the central nervous system (CNS)
NNF-funded Scope – up to DKK 38 million
› Cardiovascular and Cardiometabolic diseases (CMD & CVD)
› Infectious diseases
› Regenerative medicine
› Disease-agnostic platform technologies and research tools/methods for broader healthcare applications*
*Research within platforms/tools/methods must demonstrate that the technology, tool, or method can eventually be applied to at least one of the other NNF-scope areas.
TEAM
› THE MAIN APPLICANT must be an associate or full professor from one of the 5 Danish partner universities (see information for academics)
› PARTNERS from any other university, hospital, or non-profit company are welcome, provided they can agree to the open terms and standard agreements. All public/non-profit partners may receive a portion of the project funding
› COMPANIES provide in-kind support to the project. They do not provide or receive grant funding. Each project must have at least one company partner
IMPORTANT NOTE
A standard Project Agreement is to be entered into by all project participants before starting an ODIN project. The agreement is non-negotiable, as the terms have already been defined by the founding companies and universities for the purpose of ease-of-collaboration. The Project Agreement and all other relevant documents can be found within the About ODIN page.
2025 DOCUMENTS (OUTDATED. THE 2026 CALL OPENS 1 MARCH)
ABOUT ODIN
We unite bright minds from industry and academia to jointly create need-driven clinical research projects - and pave the way for innovative new treatments and diagnostics. We fund the best project ideas through competitive funding calls. Although companies cannot receive funding, it is free of charge to join.
The platform is sponsored by the Novo Nordisk Foundation with 180 million DKK from 2024-2029.
CONTACT ODIN
You are welcome to contact us if you have questions or comments. Reach out to odin@au.dk or find the Secretariat's direct email addresses under contacts.
Although the platform spans five Danish universities, we're based in Aarhus. Our office is located at Aarhus University, Ny Munkegade 116, Bldg 1535-117.
